

## DAFTAR PUSTAKA

- Abdelmabood, S., Fouda, A. E., Boujettif, F., & Mansour, A. (2018). Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival. *Jornal de Pediatria*, (xx).
- Al-bakrah, M., Al-mahr, M., Al-jefri, A., Salim, M. F., Osman, M., Osman, L., & El-solh, H. (2003). *Dexamethasone-Associated Toxicity during Induction Chemotherapy for Childhood Acute Lymphoblastic Leukemia Is Augmented by Concurrent Use of Daunomycin*. 2898–903.
- Anghelescu, D. L., Faughnan, L. G., Jeha, S., Relling, M. V., Hinds, P. S., Sandlund, J. T., Pui, C. H. (2011). Neuropathic Pain during Treatment for Childhood Acute Lymphoblastic Leukemia. *Pediatric Blood and Cancer*, 57(7), 1147–153.
- Aricò, M., Schrappe, M., Hunger, S. P., Carroll, W. L., Conter, V., Galimberti, S., Valsecchi, M. G. (2010). Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. *Journal of Clinical Oncology*, 28(31), 4755–61.
- Ariawati Endang; Gatot, Djajadiman, K. W. (2007). Toksisitas Kemoterapi Leukemia Limfoblastik Akut pada Fase Induksi dan Profilaksis Susunan Saraf Pusat dengan Metotreksat 1 gram. *Sari Pediatri*, (Vol 9, No 4 (2007)), 252–8.
- Arora, R. S., & Arora, B. (2016). Acute leukemia in children: A review of the current Indian data. *South Asian Journal of Cancer*, 5(3), 155–60.
- Arora, R., Eden, T., & Kapoor, G. (2009). Epidemiology of childhood cancer in India. *Indian Journal of Cancer*, 46(4), 264.
- Barr, R.D., Gomez-Almaguer, D., Jaime-Perez, J.C., Ruiz-Argüelles, G.J. (2016). Importance of Nutrition in the Treatment of Leukemia in Children and Adolescents. *Arch Med Res*, 47(8): 585–592.
- Bhojwani, D., Sabin, N. D., Pei, D., Yang, J. J., Khan, R. B., Panetta, J. C., Relling, M. V. (2014). Methotrexate-induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, 32(9), 949–59.
- Bond, J., Hough, R., Mopett, J., Vora, A., Mitchell, C., & Goulden, N. (2013). ‘Stroke-like syndrome’ caused by Intrathecal Methotrexate in Patients Treated during the UKALL 2003 trial. *Leukemia*, 27(4), 954–6.

- Ceppi, F., Langlois-Pelletier, C., Gagné, V., Rousseau, J., Ciolino, C., Lorenzo, S. De, Krajcinovic, M. (2014). Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. *Pharmacogenomics*, 15(8), 1105–16.
- Chu, Edward., DeVita, V. (2015). *Physicians' Cancer Chemotherapy Drug Manual 2015*. Burlington: Jones & Bartlett.
- Conter, F., Bartram, C., Valsecchi, M., Schrauder, A., Panzer-Grumayer, R., Moricke, K, et al. (2010). Molekuler response to treatment redefines ALL prognostic factors in children and adolescents with b-cell acute lymphoblastic leukemia results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood*, 115(16), 3206-14.
- Criteria, C. T. (2013). Common Toxicity Criteria. *Encyclopedia of Pain*, (301), 706.
- Denton, C., Rawlins, Y., Oberley, M., Bhojwani, C., Orgel, E. (2018). Predictor of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. *Pediatr Blood Cancer*, 65(3).
- Dyczynski, M., Vesterlund, M., Björklund, A.C., Zachariadis, V., Janssen, J., Gallart-Ayala, H., Daskalaki, E., Wheelock, C.E., Lehtiö, J., Grandér, D., Tamm, K.P., Nilsson, R. (2018). Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment. *Cell Death Dis.* 9.
- Eissa, H., Zhou, Y., Panetta, J., Browne, E., Jeha, S., Cheng, C., Relling, MV. (2017). The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia. *Blood Cancer Journal*, 7.
- Feijen, E. A. M., Leisenring, W. M., Stratton, K. L., Ness, K. K., Pal, H. J. H. Van Der, Caron, H. N., Hudson, M. M. (2015). Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. 33(32).
- Frisancho, A., Tracer, D. (1987). Standards of arm muscle by stature for the assessment of nutritional status of children. *American Journal of Physical Anthropology*, 73, 459-65.
- Gatot, Djajadiman., Mangunatmadja, Irawan., Wahidayat, Iskandar. (1991). *Perkembangan Mutakhir Penyakit Hematologi Anak: Naskah Lengkap Pendidikan Tambahan Berkala Ilmu Kesehatan Anak ke XXIV*. Jakarta: Bagian Ilmu Kesehatan Anak Fakultas Kedokteran Universitas Indonesia.

- Gatot, Djajadiman., Windiastuti, E. (2006). Treatment of childhood acute lymphoblastic leukemia in Jakarta: Result of modified Indonesian National Protocol 94. *Paediatrica Indonesiana*, 46, No. 7-8, 179–84.
- Gupta, S., Bonilla, M., Fuentes, S. L., Caniza, M., Howard, S. C., Barr, R., Sung, L. (2009). Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. *British Journal of Cancer*, 100(7), 1026–31.
- Gupta, S., Antillon, F. A., Bonilla, M., Fu, L., & Howard, S. C. (2011). Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. 4788–95.
- Hernández-Espinosa, D., Miñano, A., Martínez, C., Pérez-Ceballos, E., Heras, I., Fuster, J. L., Corral, J. (2006). L-asparaginase-induced antithrombin type I deficiency: Implications for conformational diseases. *American Journal of Pathology*, Vol. 169, pp. 142-53.
- Hirt, A., Leibundgut, K., Lüthy, A.R., Von Der Weid, N., Wagner, H.P., 1997. Cell birth and death in childhood acute lymphoblastic leukaemia: How fast does the neoplastic cell clone expand? *Br. J. Haematol.* 98, 999–1001.
- Huang, J., Wang, Y., Lu, Q., Rong, L., Zhang, X., Kang, M., Fang, Y. (2016). Impact of age on the survival of pediatric leukemia: an analysis of 15083 children in the SEER database. *Oncotarget*, 7(50), 484–6.
- Hunger, S. P., & Mullighan, C. G. (2015). Acute Lymphoblastic Leukemia in Children. *New England Journal of Medicine*, 373(16), 1541–52.
- Howard, Scott C., Pui, C.-H. (2002). Endocrine Complications in Pediatric Patients with Acute Lymphoblastic Leukemia. *Blood*, 16(4), 225–32.
- Jain, Puneet., Gulati, Shefalli., Seth, Rachna., Bakhshi, Sameer., Toteja, GS., Pandey, R. (2013). Vincristine-induced Neuropathy in Childhood ALL (Acute Lymphoblastic Leukemia) Survivors: Prevalence and Electrophysiological Characteristics. *Journal of Child Neurology*, 29(7), 932–7.
- Kulkani, K.P., Arora, R.S., Marwaha, R.K. (2011). Survival outcome of childhood acute lymphoblastic leukemia in India: a resource-limited perspective of more than 40 years. *JPediatr. Hematol / Oncol*, 33, 475–9.
- Laughton, S. J., Ashton, L. J., Kwan, E., Norris, M. D., Haber, M., & Marshall, G. M. (2005). *Early Responses to Chemotherapy of Normal and Malignant Hematologic Cells Are Prognostic in Children With Acute Lymphoblastic Leukemia*. 23(10).

- Li, M., Chang, H., Yang, Y., Lu, MY., Shao, P., Fu, C., et al. (2017). Infection complication in children with acute lymphoblastic leukemia treated with the Taiwan pediatric oncology group protocol. A 16 years tertiary single institution experience. *Pediatr Blood Cancer*, 64(10).
- Litbangkes. (2015). *Rencana Aksi Program Penelitian dan Pengembangan Kesehatan Tahun 2015-2019* (Badan Penelitian dan Pengembangan Kesehatan RI, ed.). Jakarta: Lembaga Penerbit Badan Litbangkes.
- Lopez-Lopez, E., Gutierrez-Camino, A., Astigarraga, I., Navajas, A., Echebarria-Barona, A., Garcia-Miguel, P., Andoin, NG., Lobo, C., Guerra-Merino, I., Martin-Guerrero, I., Garcia-Orad, A. (2016). Vincristine Pharmacokinetics Pathway and Neurotoxicity during Early phases of treatment in Pediatric Acute Lymphoblastic Leukemia. *Pharmacogenomics*, 17(7), 721–41.
- Lund, B., Åsberg, A., Heyman, M., Kanerva, J., Harila-Saari, A., Hasle, H., (NOPHO), O. behalf of the N. S. of P. H. and O. (2011). Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. *Pediatric Blood & Cancer*, 56(4), 551–9.
- Magrath, I., Shanta, V., Advani, S., Adde, M., Arya, LS., Banavali, S. (2005). Treatment of acute lymphoblastic leukemia in countries with limited resources; lessons from use of a single protocol in India over a twentyyears period. *Eur J Cancer*, 41, 1570–83.
- Marrow, B. B. (2013). Common Toxicity Criteria. *Encyclopedia of Pain*, (March 1998), 706.
- Meeske, K., Lingyun., Freyer, D., Gaynon, P., Ruccione, K., Butturini., et al. (2015). Comparative toxicity by sex among children treated for acute lymphoblastic leukemia: a report from the children's oncology group. *Pediatr Blood Cancer*, 62, 2140-9.
- Mitra, I., Pal, K., Pancholi, N., Shaikh, A., Rane, B., Tidke, P., Nair, N. K. (2017). Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin. *Annals of Oncology*, 28(9), 2119–27.
- Mia, R., Ugrasena, I D G., Permono, Bambang. (2006). *Pengelolaan Medik Anak Dengan Leukemia Dan Kemungkinan Perawatan Di RS Kabupaten*, 1–13.
- Möricke, A., Zimmermann, M., Reiter, A., Gadner, H., Odenwald, E., Harbott, J., Schrappe, M. (2005). *Prognostic Impact of Age in Children and Adolescents with Acute Lymphoblastic Leukemia: Data from the Trials ALL-BFM 86, 90, and 95. Klinische Pädiatrie* (Vol. 217).

- Murphy, A.J., White, M., Davies, P.S.W. (2010). Body composition of children with cancer. *Am J Clin Nutr*, 92(1): 55–60.
- Mushtaq, N., Fadoo, Z., & Naqvi, A. (2013). Childhood acute lymphoblastic leukaemia: Experience from a single tertiary care facility of Pakistan. *Journal of the Pakistan Medical Association*, 63(11), 1399–404.
- Muwakkit, S., Al-Aridi, C., Samra, A., Saab, R., Mahfouz, R. A., Farra, C., Jeha, S., Abboud, M. R. (2012). Implementation of an intensive risk-stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in Lebanon. *Am. J. Hematol*, 87, 678–83.
- Oudot, C., Piguet, C., Perel, Y., Gandemer, V., Debre, M., Vermeylen, C., Pautard, B., Berger, C., Schmitt, C. (2008). Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: The FRALLE 93 Study. *J. Clin. Oncol*, 26.
- Oskarsson, T., Soderhall, S., Arvidson, J., Forestier, E., Montgomery, S., Bottai, M., et al. Relaps childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. *Haematol*, 68-76.
- Ozdemir, Z., Kar, Y., Bozkurt, A., Bor, Z. (2017). Assessment of hematological toxicity in children with acute lymphoblastic leukemia, receiving treatment with ALL IC-BFM 2009 protokol. *Open Acces LibraryJournal*, 4.
- Parvareh, Maryam., Khanjani, Narges., Farahmandinia, Zahra., Nouri, B. (2015). The Survival of Childhood Leukemia and its Related factors in Kerman, Iran. *Iranian Journal of Health Sciences*, 3(4), 24–32.
- Permatasari, E., Windiastuti, E., & Satari, H. I. (2017). Survival and prognostic factors of childhood acute lymphoblastic leukemia. *Paediatrica Indonesiana*, 49(6), 365.
- Plourde PV, Jeha S, Hijiya N, et al. (2014). Safety profile of asparaginase *Erwinia Chrysanthemi* in a large compassionate use trial. *Pediatr Blood Cancer*, 1232-8.
- Pribnow, A., Ortiz, R., Baes, L., Mendieta, L., Fineman, S. (2017). Effects of malnutrition on treatment related morbidity and survival of children with cancer in Nicaragua. *Pediatr Blood Cancer*, 64.
- Pui, C. H., Pei, D., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Relling, M. V. (2010). Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. *Leukemia*, 24(2), 371–82.

- Pui, C.H., Robison, L. L., & Look, A. T. (2008). Acute lymphoblastic leukaemia. *The Lancet*, 371(9617), 1030–43.
- Pui, C., Burghen, W., Bowman. (1981). Risk factor for hyperglycemia in children with leukemia receiving L asparaginase and prednisone. *J Pediatr*, 99(1), 46–50.
- Puspita, A., Mediani, H., Nurhidayah, I. (2018). Correlation between nutritional states with hematological toxicity in children with acute lymphoblastic leukemia. *Jurnal Pendidikan Keperawatan Indonesia*, 4(1), 22–9.
- Raetz, Elizabeth A., Salzer, W. L. (2010). Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. *Journal of Pediatric Hematology/Oncology*, 32(7), 554–63.
- Raja, R. A., Schmiegelow, K., & Frandsen, T. L. (2012). Asparaginase-associated Pancreatitis in Children. *British Journal of Haematology*, 159(1), 18–27.
- Sala, A., Rossi, E., Antillon, F., Molina, A., De Maselli, T., Bonilla, M., Hernandez, A., Ortiz, R., Pacheco, C., Nieves, R., Navarrete, M., Barrantes, M., Pencharz, M.G., Barr, R. (2012). Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: A perspective from Central America. *Eur J Cancer*, 48(2): 243–52.
- Salvador, C., Meister, B., Crazzolaro, R., & Kropshofer, G. (2012). Management of Hypertriglyceridemia in Children with Acute Lymphoblastic Leukemia Under Persistent Therapy with Glucocorticoids and L-Asparaginase during Induction Chemotherapy. In *Pediatric blood & cancer* (Vol. 59).
- Silverman, L. B., Gelber, R. D., Dalton, V. K., Asselin, B. L., Barr, R. D., Clavell, L. A., Sallan, S. E. (2001). Improved Outcome for Children with Acute Lymphoblastic Leukemia: Results of Dana-Farber Consortium Protocol 91-01. *Blood*, 97(5), 1211–18.
- Supriyadi, Eddy., Widjajanto, PH., Purwanto, I., Cloos, J. (2011). Incidence of Childhood Leukemia in Yogyakarta, Indonesia, 1998–2009. *Pediatr Blood Cancer*, 57, 588–93.
- Sutaryo, Mulatsih S, Setiawan S. (2017). Manual obat sitostatika injeksi. Fakultas Kedokteran Universitas Gadjah Mada/RSUP dr. Sardjito Yogyakarta.
- Stary, J., Zimmermann, M., Campbell, M., Castillo, L., Dibar, E., Donka, S., et al. (2002). Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial all ic-bfm. *J Clin Oncol*, 32(3), 174–84.



- Stow, P., Key, L., Chen, X., Pan, Q., Neale, G. A., Coustan-Smith, E., Campana, D. (2010). Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. *Blood*, 115(23), 4657–63.
- Van Cutsem, E., Arends, J. (2005). The causes and consequences of cancer associated malnutrition. *Eur J Oncol Nurs*, 9(SUPPL. 2).
- Van de Velde, M. E., Kaspers, G. L., Abbink, F. C. H., Wilhelm, A. J., Ket, J. C. F., & van den Berg, M. H. (2017). Vincristine-induced Peripheral Neuropathy in Children with Cancer: A Systematic Review. *Critical Reviews in Oncology/Hematology*, 114, 114–30.
- Widiaskara, IM., Permono, B., Urgasena, IDG., & Ratwita, M. (2016). Luaran Pengobatan Fase Induksi Pasien Leukemia Limfoblastik Akut pada Anak di Rumah Sakit Umum Dr. Soetomo Surabaya. *Sari Pediatri*, 12(2), 128.
- Wijayanti, L. P., & Eddy, S. (2017). Faktor Prognostik dan Kesintasan Pasien Leukemia Limfoblastik Akut Anak di RSUP Dr. Sardjito, Yogyakarta, 2010–2015. *Indonesian Journal of Cancer*, 11(4), 145–50.
- Widnyana, A. A. N. K. P. (2015). Angka kesintasan dan faktor yang memengaruhi pasien leukemia limfoblastik akut pada anak di RS Sanglah tahun 2010-2012.
- Woo, J. S., Alberti, M. O., & Tirado, C. A. (2014). Childhood B-acute lymphoblastic leukemia: A genetic update. *Experimental Hematology and Oncology*, 3(1), 1–14.
- Yeoh, A., Collins, A., Fox, K., Shields, S., Ritchie, P., Kirby, M., & Revesz, T. (2017). Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia. *Pediatric Hematology and Oncology*, 34(1), 38–42.
- Yudhani, R. D. (2014). Farmakogenomik dan Terapi Kanker. *Continuing Development Professional*, 41(6), 412–15.
- Zawitkowska, Joanna et al. (2019). Infectious Grade 3 and 4 toxicity profiles during therapy of childhood acute lymphoblastic leukemia. *International Institute of Anticancer Research*, 25 (10), 774 – 9.
- Zhang, YL., Zhao, WL., Nie, SS., Guo, DD., Ji, ZH., Chai, Y. (2011). Analysis of clinical features and prognostic significance of childhood T-lineage acute lymphoblastic leukemia. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*, 19, 1496–500.

Zuckerman, T., & Rowe, J. (2014). Pathogenesis and prognostication in acute lymphoblastic leukemia. *F1000Prime Reports*, 6(July), 3–7.